Pharmaceutical company VIVUS (VVUS) has been officially notified that the European Medicines Agency (EMA) will not approve its weight-loss drug Qsymia. In a previous video, we covered what this news could mean for VIVUS going forward -- but what impact does it have on its chief rival, Arena Pharmaceuticals (ARNA)? Does this mean that Arena's drug Belviq will dominate the market if it gains EMA approval next year? Instead, could this decision mean that all weight-loss drugs -- including Belviq -- will be intensely scrutinized before they can hit the European market?
In the following video, Health Care Analysts Max Macaluso and David Williamson discuss how this news could affect Arena's future.
